T. Rowe Price Associates
NPCE icon

T. Rowe Price Associates’s Neuropace NPCE Stock Holding History

T. Rowe Price Associates’s Portfolio NPCE Stock Details NPCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$346K Buy
21,764
+4,456
+26% +$71.7K ﹤0.01% 2793
2026
Q1 		$228K Buy
17,308
+2,472
+17% +$37.1K ﹤0.01% 2795
2025
Q4 		$230K Buy
14,836
+2,778
+23% +$37.1K ﹤0.01% 2762
2025
Q3 		$125K Hold
12,058
– – ﹤0.01% 2887
2025
Q2 		$135K Buy
+12,058
New +$151K ﹤0.01% 2831

Other funds holding NPCE

PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

T. Rowe Price Associates's NPCE Position: Q2 2026 in Review

T. Rowe Price Associates increased its Neuropace (NPCE) stake by 26% in Q2 2026, buying an estimated $71.7K and bringing the position to 21,764 shares worth $346K. The position accounts for ﹤0.01% of the portfolio, ranked #2793.

T. Rowe Price Associates first reported a position in NPCE in Q2 2025 and has held it in 5 quarters since. 112 funds tracked by Wall St. Rank hold NPCE as of Q2 2026.

  • T. Rowe Price Associates held 21,764 shares of Neuropace worth $346K as of Q2 2026.
  • T. Rowe Price Associates bought 4,456 Neuropace shares in Q2 2026, an estimated $71.7K.
  • Neuropace made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #2793 holding.
  • T. Rowe Price Associates first reported a position in Neuropace in Q2 2025 and has held it in 5 quarters since.
  • 112 funds tracked by Wall St. Rank held Neuropace as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.